Evonile Pharma Limited (BOM:500672)
India · Delayed Price · Currency is INR 1,762.40
+48.05 (2.80%)
At close: Nov 6, 2026
Evonile Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 3,363 | 3,543 | 3,563 | 3,351 | 3,787 | 3,999 |
Other Revenue | -35.3 | - | - | - | - | - |
| 3,328 | 3,543 | 3,563 | 3,351 | 3,787 | 3,999 | |
Revenue Growth | -6.20% | -0.55% | 6.33% | -11.53% | -5.28% | 4.86% |
Cost of Revenue | 2,038 | 1,984 | 2,028 | 2,000 | 2,017 | 1,782 |
Gross Profit | 1,289 | 1,560 | 1,535 | 1,351 | 1,771 | 2,217 |
Selling, General & Admin | 313.1 | 228.3 | 211.3 | 250.1 | 419.2 | 1,097 |
Other Operating Expenses | 529 | 369 | 407.8 | 443.9 | 686.2 | 789.3 |
Operating Expenses | 893.5 | 615.5 | 639.3 | 721.8 | 1,170 | 1,979 |
Operating Income | 395.9 | 944.1 | 895.2 | 629.2 | 600.8 | 237.7 |
Interest Expense | -59.4 | -12.6 | -7.7 | -14.9 | -17.5 | -48.3 |
Interest & Investment Income | 382.2 | 382.2 | 408.8 | 551.9 | 543.6 | 209.6 |
Currency Exchange Gain (Loss) | -22.6 | -22.6 | -2.9 | -2.7 | -10.6 | 1.4 |
Other Non Operating Income (Expenses) | 5.5 | 5.5 | 9.7 | 6 | 8.6 | 4.8 |
EBT Excluding Unusual Items | 701.6 | 1,297 | 1,303 | 1,170 | 1,125 | 405.2 |
Merger & Restructuring Charges | - | - | - | - | - | -496.4 |
Gain (Loss) on Sale of Assets | - | - | 1.1 | 32.1 | 28.9 | -1.4 |
Other Unusual Items | -682.6 | - | - | 26.8 | - | 54.4 |
Pretax Income | 19 | 1,297 | 1,304 | 1,228 | 1,154 | -38.2 |
Income Tax Expense | 58.9 | 364.8 | 295.2 | 376.5 | 120.2 | -1 |
Earnings From Continuing Operations | -39.9 | 931.8 | 1,009 | 851.9 | 1,034 | -37.2 |
Net Income | -39.9 | 931.8 | 1,009 | 851.9 | 1,034 | -37.2 |
Net Income to Common | -39.9 | 931.8 | 1,009 | 851.9 | 1,034 | -37.2 |
Net Income Growth | - | -7.65% | 18.44% | -17.58% | - | - |
Shares Outstanding (Basic) | 25 | 25 | 25 | 25 | 25 | 25 |
Shares Outstanding (Diluted) | 25 | 25 | 25 | 25 | 25 | 25 |
Shares Change | 0.02% | - | - | - | - | - |
EPS (Basic) | -1.62 | 37.74 | 40.87 | 34.50 | 41.86 | -1.51 |
EPS (Diluted) | -1.62 | 37.74 | 40.87 | 34.50 | 41.86 | -1.51 |
EPS Growth | - | -7.65% | 18.44% | -17.58% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -11,406 | 463.9 | 745.7 | 1,134 | 444.9 | 381.7 |
Free Cash Flow Per Share | -461.93 | 18.79 | 30.20 | 45.93 | 18.02 | 15.46 |
Dividend Per Share | - | - | 25.000 | 25.000 | 10.000 | 10.000 |
Dividend Growth | - | - | 0% | 150.00% | 0% | 0% |
Gross Margin | 38.75% | 44.02% | 43.07% | 40.32% | 46.75% | 55.44% |
Operating Margin | 11.90% | 26.65% | 25.13% | 18.78% | 15.86% | 5.94% |
Profit Margin | -1.20% | 26.30% | 28.32% | 25.42% | 27.29% | -0.93% |
Free Cash Flow Margin | -342.76% | 13.09% | 20.93% | 33.84% | 11.75% | 9.55% |
EBITDA | 432.9 | 948.5 | 899.9 | 631 | 618.4 | 256.5 |
EBITDA Margin | 13.01% | 26.77% | 25.26% | 18.83% | 16.33% | 6.42% |
D&A For EBITDA | 37 | 4.4 | 4.7 | 1.8 | 17.6 | 18.8 |
EBIT | 395.9 | 944.1 | 895.2 | 629.2 | 600.8 | 237.7 |
EBIT Margin | 11.90% | 26.65% | 25.13% | 18.78% | 15.86% | 5.94% |
Effective Tax Rate | 310.00% | 28.13% | 22.63% | 30.65% | 10.42% | - |
Revenue as Reported | 3,716 | 3,931 | 3,982 | 3,968 | 4,369 | 4,331 |
Advertising Expenses | - | 16.8 | 23.4 | 19.4 | 61 | 74.6 |